Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS)
REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, reinforce the company's successful approach to understanding tumor biology—now across four different cancer types—and highlight the following:
- Unique value and practice-changing impact of the Oncotype DX test in breast cancer
- Breadth of clinical evidence for the Oncotype DX test in colon cancer
- Continued adoption and clinical utility of Oncotype DX across healthcare systems worldwide
- Further evidence of the robustness of the Oncotype DX prostate cancer test
Presentation details are as follows (all times are in Central Daylight Savings Time):
Poster Presentation: "Prediction of recurrence with the Oncotype DX Recurrence Score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy" (Abstract #11052)
- Lead Author: Frederique Penault-Llorca, M.D., Centre Jean Perrin, France
- Time: Saturday, May 31, 1:15 p.m. - 5 p.m.
- Location: S Hall A2; Poster Board: #334
Poster Highlights Session: "Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial" (Abstract #524)
- Lead Author: Oleg Gluz, M.D., West German Study Group (WSG), Germany
- Time: Sunday, June 1, 8 a.m. – 11 a.m.
- Location: E Arie Crown Theater
Oral Presentation: "A pilot laboratory study comparing the 21-gene assay and PAM50-ROR" (Abstract #11003)
- Lead Author: R. Prasad
- Time: Monday, June 2, 4 p.m. - 4:12 p.m.
- Location: S100bc
Poster Highlights Session: "Recurrence Score and quantitative ER expression predicts late distant recurrence risk in ER+ breast cancer after five years of tamoxifen" (Abstract #11024)
- Lead Author: Norman Wolmark, M.D., the National Surgical Adjuvant Breast and Bowel Project (NSABP)
- Time: Monday, June 2, 8 a.m. - 11 a.m.
- Location: S405; Poster Board: #13
Poster Presentation: "Clinical utility of the 12-gene DCIS Score assay: impact on treatment (Tx) recommendations" (Abstract #11050)
- Lead Author: Michael Alvarado, M.D., University of California, San Francisco Medical Center
- Time: Saturday, May 31, 1:15 p.m. - 5 p.m.
- Location: S Hall A2; Poster Board: #332
Poster Presentation: "Use of the 21-Gene Recurrence Score (RS) assay and chemotherapy (CT) across healthcare (HC) systems" (Abstract #6580)
- Lead Author: Anosheh Afghahi, Stanford University, School of Medicine
- Time: Monday, June 2, 1:15 p.m. - 5 p.m.
- Location: S Hall A2; Poster Board: #43
Poster Presentation: "The 12-gene colon cancer assay validation and utility: summary of clinical evidence" (Abstract #3547)
- Lead Author: Emily Burke, Genomic Health
- Time: Saturday, May 31, 8 a.m. - 11:45 a.m.
- Location: S Hall A2; Poster Board: #10
Poster Presentation: "A biopsy-based molecular diagnostic test predicts aggressive prostate cancer despite variability in pathology assessment" (Abstract #5082)
- Lead Author: Jeffrey Simko, M.D., PhD, University of California, San Francisco
- Time: Monday, Jun 2, 1:15 p.m. - 5 p.m.
- Location: S Hall A2; Poster Board: #211
Oral Presentation: "Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I-III clear cell renal cell carcinoma (ccRCC)" (Abstract #4502)
- Lead Author: Bernard Escudier,M.D., Institut Gustave Roussy
- Time: Monday, June 2, 10:33 a.m. - 10:45 a.m.
- Location: E Hall D1
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring. Genomic Health's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of December 31, 2013, more than 19,000 physicians in over 70 countries had ordered approximately 420,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements..
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.